CVS Health Corp (NYSE: CVS) has reported earnings for its second fiscal quarter (ending June 30) of $1.41 versus $1.48 for the same period a year ago — a decline of -5%. This result fell short of the consensus estimate of $1.73 by $-0.32. For the latest four quarters through June 30, E.P.S. were $5.64 versus $2.34 for the same period a year ago — an increase of 141%.
Recent Price Action
CVS Health Corp (NYSE: CVS) stock declined by -3.2% on 8/7/24. The shares closed at $56.47. Moreover, trading volume in this decline was above average at 144% of normal. The stock has been extremely weak relative to the market over the last nine months and has declined -10.6% during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to be above the cost of capital, CVS is expected to continue to be a major Value Builder.
CVS Health has a current Value Trend Rating of C (Neutral). This rating combines very contradictory signals from two proprietary PTR measures of a stock’s attractiveness. CVS Health has a very high Appreciation Score of 91 but a very low Power Rating of 2, producing the Neutral Value Trend Rating.
Rating Review
In light of this discouraging new earnings information and negative market action we are reviewing our current Overall Rating of C. We would view the shares with caution pending completion of this review in the next several days.
Be the first to comment